Nitresan (Nitrendipine)

Nitrendipine, the active ingredient in Nitresan, is a calcium channel blocker presented as an oral tablet for systemic use. It lowers elevated blood pressure by relaxing vascular smooth muscle and is indicated for the management of essential hypertension in adult patients. It is marketed within the European Union and conforms to the relevant pharmacopeial standards.

GNH USA supplies Nitresan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality across global markets.

Nitrendipine is employed to manage disorders of the cardiovascular system, primarily hypertension.

- Essential hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. - Isolated systolic hypertension: primarily reduces elevated systolic pressure in older adults. - Hypertension in the elderly: provides effective blood pressure control with once‑daily dosing.

Nitrendipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache often occurring early in therapy. - Flushing: transient warmth and redness of the face or neck. - Peripheral edema: swelling of ankles or lower legs due to fluid accumulation. - Dizziness or light‑headedness: especially when standing quickly.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack, particularly in patients with coronary artery disease. - Allergic reactions: rash, itching, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes indicating possible liver injury.

When prescribing Nitrendipine, clinicians should consider several safety measures to minimize risk.

- Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Gradual dose adjustment: titrate dose slowly to achieve target pressure while limiting side effects. - Hepatic impairment: use with caution and consider lower doses in patients with liver disease. - Elderly patients: start at the lowest effective dose due to increased sensitivity. - Concomitant severe aortic stenosis: contraindicated because of risk of marked hypotension. - Store at room temperature: keep tablets in the original container, protect from moisture and heat.

Nitrendipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma levels and increase toxicity. - Grapefruit juice: can markedly increase Nitrendipine concentration, leading to severe hypotension. - Concurrent use with other potent antihypertensives (e.g., clonidine): may cause excessive blood pressure lowering.

Moderate Interactions (Monitor Closely): - Diuretics: additive blood pressure‑lowering effect may require dose adjustment. - Beta‑blockers: combined therapy can enhance hypotensive response. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect of Nitrendipine.